Clinical response in patients with ovarian cancer treated with metronomic chemotherapy. - Wikidata - awgldk - TriplyDB

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

http://www.wikidata.org/entity/Q37679904

about

Metronomic cyclophosphamide-induced long-term remission after recurrent high-grade serous ovarian cancer: A case study.Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway.

P2860

Q47124967-FD762703-2463-436D-9AA5-F91D76954E58 Q52649728-0368765E-3168-487B-96BA-A044530CA0A6

P2860

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

http://www.wikidata.org/entity/Q37679904

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

@en

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

@nl

type

label

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

@en

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

@nl

prefLabel

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

@en

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

@nl

P1433

Q37679904-58947532-B1D1-4A24-AC73-67506AC790C5

P1476

Q37679904-316955BE-2AC7-4028-8EB3-D21727929016

P2093

Q37679904-7EE01D50-E7D4-4581-B6FE-C7CD5BBA6106

Q37679904-9D241EE5-DB81-41C0-8996-836DF0F4A3C5

Q37679904-A4E586C8-9A7B-42D0-A475-491579270029

Q37679904-B0390A1F-B72F-4C94-A8F3-ECA46862A8FF

P2860

Q37679904-003D377D-0030-43A8-9C5F-D886865ED18F

Q37679904-11BB3335-49FB-4F04-AE9F-721666C28934

Q37679904-20A2D3E6-3AD4-460E-B4D2-3A12D7C6E0EE

Q37679904-20F5C4E1-7E27-4D67-8EDD-2C729711E76D

Q37679904-2EFA48EF-4D41-4D79-97CB-474CAEB7F598

Q37679904-37A046F7-84D0-4B3F-9987-042630F0556A

Q37679904-44CC2D73-62F9-48A0-827C-1FEB9FD77CC5

Q37679904-4A52661B-7389-4920-A8A9-1D08EA03116B

Q37679904-4C35219B-CF3E-40BB-B482-9289AF47E2DC

Q37679904-4D707710-3E6F-4C9D-9297-CE4A33A12809

P304

Q37679904-B4F149D2-BA74-488F-8CAC-7A24121C1F96

P31

Q37679904-4A1A66F6-62DC-4761-B44C-9950084A1A39

P356

Q37679904-11D59689-EAF3-4328-A66E-8EA37A59A623

P478

Q37679904-9FDC45D1-5817-4BA7-933A-41C50FB6131F

P577

Q37679904-E4576EB9-EC99-441B-967C-9F1CDDA70A18

P698

Q37679904-41539148-ADD3-4DB7-95B6-B2D8909DC6D6

P921

Q37679904-B33945B9-857E-42EC-AFF4-D171C9D2F9A3

Q37679904-F20AC477-6F87-4919-A537-8B6CD45BD692

P932

Q37679904-DD50F69D-DA2F-4893-84C6-DF42B9D64030

P356

ECANCER.2017.723

P1433

Ecancermedicalscience

P1476

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

@en

P2093

Carlos María Alasino

http://www.w3.org/2001/XMLSchema#string

Herman Andrés Perroud

http://www.w3.org/2001/XMLSchema#string

O Graciela Scharovsky

http://www.w3.org/2001/XMLSchema#string

Viviana Rosa Rozados

http://www.w3.org/2001/XMLSchema#string

P2860

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

Cancer statistics, 2015

Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.

Targeted therapy in ovarian cancer.

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

The Repurposing Drugs in Oncology (ReDO) Project.

Angiogenesis in epithelian ovarian cancer.

P304

723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2017.723

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28275392

http://www.w3.org/2001/XMLSchema#string

P921

P932

5336390

http://www.w3.org/2001/XMLSchema#string